# Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

> **NCT02343445** · PHASE2 · COMPLETED · sponsor: **Parion Sciences** · enrollment: 142 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** P-1037
- **DRUG:** Hypertonic Saline
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02343445
- **Lead sponsor:** Parion Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2021-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343445, "Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02343445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*